SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2257Here's their latest slides... p.widencdn.net One thing they emphasize is thJamesK-1/24/2018
2256I think its 50:50 if it beats rapatha but if it does maybe praulent not a compleFelix B-1/24/2018
2255And again, MDCO's inclirisan (got Orphan, seekingalpha.com ), but can not enMiljenko Zuanic-1/23/2018
2254In few years China/Korea (India to follow) will flood WW-market with biologic/biMiljenko Zuanic11/23/2018
2253REGN1500 ( evinacumab), PLAN FOR P3: clinicaltrials.gov Why placebo as comparaMiljenko Zuanic-1/22/2018
2252Odyssey outcome (CVOT) to be featured as late-breaker at ACC-18 (Saturday, 3/10)Miljenko Zuanic-1/22/2018
2251Can't believe it, someone is comparing EPA supplement company AMRN to R&Miljenko Zuanic-1/21/2018
2250To make it clear, in trial: clinicaltrials.gov They already have triple combinMiljenko Zuanic-1/16/2018
2249Will see how long it will take them to emend protocol? REGN is in control of theMiljenko Zuanic-1/16/2018
2248Yes, they should be testing chemo ± REGN 2810 (not head-to-head).DewDiligence_on_SI-1/16/2018
2247In light of the latest Keytruda/chemo results for any PDL1 level in 1L NSCLC, REMiljenko Zuanic-1/16/2018
2246Last time BI Ridgefield facility were inspected by FDA was 2-2017, no 483 letterMiljenko Zuanic-1/11/2018
2245I know their Ridgefield site was going through a lot of turnover and struggles tFelix B-1/10/2018
2244BI is serious player in antibody manufacturing business, regardless where are maMiljenko Zuanic11/10/2018
2243"Boehringer Ingelheim’s world-class biopharmaceutical manufacturing facilitFelix B-1/10/2018
2242BGNE PD-1 candidate, BGBA317, is closing in: finance.yahoo.com Miljenko Zuanic-1/10/2018
2241Musings on MYL/MNTA's decision to pursue an Eylea FoB: siliconinvestor.comDewDiligence_on_SI-1/8/2018
2240CHRS is another company developing an Eylea biosimilar, although its program is DewDiligence_on_SI-1/8/2018
2239I intend to keep most of my REGN shares as well. It's been a long ride fromBiotech Jim-1/8/2018
2238<Today investors vote: NO! Clearly!> And as regular contrarian, my vote iMiljenko Zuanic11/8/2018
2237Would investment in "spending" ever pay off at REGN??? files.shareholdMiljenko Zuanic-1/8/2018
2236Go BCRX, go: finance.yahoo.comMiljenko Zuanic-1/5/2018
2235There is no sustained release formulation. 6-8w (up to 12w in some cases) is finMiljenko Zuanic-1/4/2018
2234I agree I thought a biosimilar trap would be difficult to produce but I am no exFelix B-1/3/2018
2233<I checked REGN balance shits, and am happy that they improve it. Hope, it maMiljenko Zuanic-1/3/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News